Researchers analyzed data from a 28-day clinical study of 146 patients, half of which took inhaled budesonide — sold as AstraZeneca’s Pulmicort — twice a day.
The drug cut the risk of urgent care or hospitalization by 90 percent within the study period and was also tied to a “quicker resolution of fever, symptoms, and fewer persistent symptoms.”
The study findings were published Feb. 4 on the medRxiv preprint server. The study has yet to be peer reviewed.
More articles on patient safety and outcomes:
Roche arthritis drug reduces COVID-19 death risk, Oxford research suggests
FDA updates guidance on ventilator splitting
Joint Commission issues alert on providing equitable care during pandemic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
